“This collaboration reiterates MyMD’s dedication to partnering with top-tier academic institutions to study MYMD-1 as a treatment for various high-impact conditions and diseases,” Chapman said. Nasser Ibrahim Al-Rashid Chair in Ophthalmology at Bascom Palmer Eye Institute, said in a news release.Ĭhapman added in the news release that after the initial pre-clinical study, the potential exists to collaborate with Bascom Palmer on large patient studies in the future. “Through this partnership with MYMD, we look forward to investigating the potential utility of an oral TNF-alpha inhibitor in animal models of eye-related diseases,” David Tse, M.D., FACS, professor of Ophthalmology and the Dr. “Bascom Palmer is virtually unmatched as a world leader in vision research and care and their interest in MYMD-1 validates our belief in the potential of the drug for autoimmune and inflammatory conditions.” “We are excited about this agreement with our country’s top eye institute to test our lead drug candidate MYMD-1 in ophthalmology,” Chris Chapman, MD, president, director and chief medical officer of MyMD, said in a news release. The reported incidence of TON ranges from 1.5% to 4% following head trauma 1, and each year an estimated 2.8 million Americans sustain a traumatic brain injury 2.
Visual impairment is usually caused by blunt force trauma to the head. TON is a condition caused by injury to the optic nerve, resulting in partial or complete vision loss.
announced recently that it has entered into a material transfer agreement (MTA) with Bascom Palmer Eye Institute of Miami, Florida to collaborate on a pre-clinical study using MYMD-1 as a potential treatment for traumatic optic neuropathy (TON).Īccording to the news release, the project is fully funded by Bascom Palmer Eye Institute.
0 kommentar(er)
